DelveInsight’s, “Malignant Pleural Mesothelioma (MPM) – Pipeline Insight, 2020,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Malignant Pleural Mesothelioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
• Global coverage
Malignant Pleural Mesothelioma Understanding
Malignant Pleural Mesothelioma (MPM): Overview
Pleural mesothelioma is a type of cancer caused by asbestos fibers becoming embedded in the lining of the lungs. Over time, the fibers may cause inflammation and scarring. As the scarring worsens, it may develop into mesothelioma tumors. Most pleural mesothelioma patients are diagnosed with the epithelioid cell type, which is the most common. Epithelioid cells typically form in solid sheets or cord arrangements, meaning they adhere closely together and don’t metastasize as quickly. They are also the most responsive to treatment. Typically, pleural mesothelioma patients with the epithelioid cell type survive 19 months.
The other cell types, sarcomatoid and biphasic, are less common and indicate a worse prognosis than epithelioid. Sarcomatoid mesothelioma doesn’t respond well to treatment and metastasizes aggressively, leaving patients with an average prognosis of 8 – 10 months.
Symptoms
After asbestos exposure, it can take 10 to 50 years for pleural mesothelioma symptoms to present. Symptoms typically first present in the chest cavity and respiratory system.
• Shortness of breath
• Chest pain or painful breathing
• Persistent dry or raspy cough
• Coughing up blood
• Difficulty swallowing
• Pain in the lower back or rib area
• Unexplained weight loss and fatigue
• Swelling of the face or arms
• Night sweats or fever
• Lumps under the skin on the chest
Diagnosis
Currently, a biopsy is the only way to verify a malignant pleural mesothelioma diagnosis. Tests like a thoracentesis or thoracoscopy may be performed to take a tissue or fluid sample for analysis. For a thoracentesis, a doctor will insert a fine needle to remove fluid buildup in the chest. A thoracoscopy is more invasive. Doctors insert a viewing tube called a thoracoscope into the chest to inspect the lungs and surrounding pleura. They can then remove a tissue sample or draw fluid for analysis. After the biopsy, a pathologist will study the cells to make a definitive diagnosis, including cell type and how the disease is expected to progress.
Treatment
Although there is no cure for mesothelioma, some patients live much longer with treatments. Combining several treatments, such as surgery, chemotherapy and radiation therapy, has helped some people live for years. Surgery is controversial and limited to patients with early stage disease and good functional status. Palliative care and symptom management are essential and the control of pleural effusions is an important factor. Clinical trials offer access to new treatments such as immunotherapy.
• In 2004, FDA approved alimta for use with cisplatin, for the treatment of malignant pleural mesothelioma
Malignant Pleural Mesothelioma Emerging Drugs Chapters
This segment of the Malignant Pleural Mesothelioma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Malignant Pleural Mesothelioma Emerging Drugs
• MTG201: Momotaro-Gene Inc.
MTG201 is a novel investigational gene therapy with unique dual mechanisms of action capable of addressing a range of cancers. The drug candidate leverages the company’s proprietary adenoviral vector technology platform to deliver the Reduced Expression in Immortalized Cells/Dickkopf-3 gene (REIC/Dkk-3 gene) into cancer cells, where the expression of the gene has been shown to be markedly downregulated. The resulting increase in REIC/Dkk-3 gene expression in cancer cells triggers immunogenic cell death selectively in cancer cells.
At the same time, increased expression of REIC/Dkk-3 gene in normal cell components in tumor tissue promotes anti-tumor immunity by activating dendritic cells and natural killer (NK) cells while suppressing immune suppressive regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSC). Based on these novel dual mechanisms, MTG201 is believed to be well positioned to work synergistically with checkpoint inhibitors such as nivolumab.
• YS110: Kissei Pharmaceutical Co., Ltd.
YS110 is a humanized, immunoglobulin G1 (IgG1) monoclonal antibody directed against the extracellular domain of dipeptidyl peptidase 4 (CD26; DPP4; DPP IV), with potential antineoplastic activity. Upon administration of anti-CD26 monoclonal antibody YS110, this antibody targets and binds to CD26 expressed on tumor cells. This inhibits CD26 activity and causes internalization of CD26-YS110. This leads to cell cycle arrest, lysis and inhibition of growth in CD26-positive tumor cells. YS110 also induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against CD26-expressing tumor cells. CD26, a 110-kDa, type II transmembrane glycoprotein, is overexpressed in a variety of cancer cell types while absent in normal, healthy cells and plays a key role in tumor cell growth, migration, invasion and survival. It also plays a major role in the regulation of T-cell activity.
Further product details are provided in the report……..
Malignant Pleural Mesothelioma: Therapeutic Assessment
This segment of the report provides insights about the different Malignant Pleural Mesothelioma drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Malignant Pleural Mesothelioma
There are approx. 25+ key companies which are developing the therapies for Malignant Pleural Mesothelioma. The companies which have their Malignant Pleural Mesothelioma drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Momotaro-Gene Inc., Merck, Bristol-Myers Squibb, Ono Pharmaceutical, PrECOG, AstraZeneca etc.
Phases
DelveInsight’s report covers around 25+ products under different phases of clinical development like
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Malignant Pleural Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Subcutaneous
• Intravenous
• Intramuscular
• Intratumoral
• Oral
• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal antibodies
• Vaccines
• Small molecules
• Immunotherapies
• Gene therapy

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Malignant Pleural Mesothelioma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Malignant Pleural Mesothelioma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Malignant Pleural Mesothelioma drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Malignant Pleural Mesothelioma R&D. The therapies under development are focused on novel approaches to treat/improve Malignant Pleural Mesothelioma.
• In September 2020, the European Medicines Agency (EMA) validated a type II variation application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the treatment of patients with previously untreated, unresectable malignant pleural mesothelioma (MPM). Validation of the application confirms the submission is complete and begins the EMA’s centralized review process.
Malignant Pleural Mesothelioma Report Insights
• Malignant Pleural Mesothelioma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Malignant Pleural Mesothelioma Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Malignant Pleural Mesothelioma drugs?
• How many Malignant Pleural Mesothelioma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Malignant Pleural Mesothelioma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Malignant Pleural Mesothelioma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Malignant Pleural Mesothelioma and their status?
• What are the key designations that have been granted to the emerging drugs?
Key Players
• Momotaro-Gene Inc.
• Kissei Pharmaceutical Co., Ltd.
• Oncovir, Inc.
• Trizell Ltd.
• Merck
• Bristol-Myers Squibb
• Theradex
• Targovax Oy
• Hoffmann-La Roche
Key Products
• MTG201
• YS110
• Poly-ICLC (Hiltonol) Vaccine
• rAd-IFN
• Nivolumab and ipilimumab
• ONCOS-102